Hospitals

ProvideGx® Partners with Pfizer Inc. to Secure the Supply of Five Essential Medications

Thursday, January 21, 2021 - 6:00pm

Fentanyl is a controlled substance used to prevent pain for short periods of time, usually before anesthesia is administered or immediately after surgical procedures.

Key Points: 
  • Fentanyl is a controlled substance used to prevent pain for short periods of time, usually before anesthesia is administered or immediately after surgical procedures.
  • The 0.9 percent sodium chloride injection is used to dilute other medications before injection.
  • These five medications are critical for patient care and in some cases are necessary as part of COVID-19 treatments.
  • Our partnership with Pfizer will help ensure a sustainable supply of five drugs that are essential not just during the pandemic, but also for routine and elective care longer term.

The Vistria Group and Excellere Partners Invest in SCA Pharmaceuticals

Thursday, January 21, 2021 - 4:59pm

The Vistria Group and Excellere Partners have purchased all of the issued and outstanding equity interests of SCA Pharma.

Key Points: 
  • The Vistria Group and Excellere Partners have purchased all of the issued and outstanding equity interests of SCA Pharma.
  • We are very pleased that as we continue our expansion efforts and improvements in our efficiencies, our new partnership with The Vistria Group and Excellere will allow us to accelerate these efforts, said Milton Boyer, CEO of SCA Pharma.
  • We look forward to working with Excellere to take the high standards set by SCA even further, said Jon Maschmeyer, Partner at Vistria.
  • An emerging national leader in compounded pharmaceuticals, SCA Pharma previously was wholly owned by Enhanced Healthcare Partners.

Milestone Achieved: 500 Endoscopic Sleeve Gastroplasty Procedures at WakeMed Cary Hospital

Thursday, January 21, 2021 - 3:31pm

Today, gastroenterologist Christopher McGowan, M.D., of True You Weight Loss in Cary, NC, performed his 500th Endoscopic Sleeve Gastroplasty at the Advanced Gastrointestinal Center at WakeMed Cary Hospital, making him the first and only physician in the country to reach this milestone.

Key Points: 
  • Today, gastroenterologist Christopher McGowan, M.D., of True You Weight Loss in Cary, NC, performed his 500th Endoscopic Sleeve Gastroplasty at the Advanced Gastrointestinal Center at WakeMed Cary Hospital, making him the first and only physician in the country to reach this milestone.
  • WakeMed Cary Hospital was the first hospital in North Carolina where the first ESG procedures were performed in 2018.
  • True You Weight Loss and WakeMed Cary Hospital, together, are currently the only facilities that offer ESG throughout the state.
  • WakeMed Cary Hospitals Advanced Gastrointestinal Center not only provides diagnostic and treatment for digestive diseases, but specializes in minimally invasive procedures including ESG for weight loss.

U.S. Physical Therapy, Inc. Schedules Fourth Quarter and Year Ended 2020 Release and Conference Call for Thursday, February 25, 2021

Thursday, January 21, 2021 - 3:00pm

To listen to the live call, please go to www.usph.com and click on conference calls under the Investor Relations section.

Key Points: 
  • To listen to the live call, please go to www.usph.com and click on conference calls under the Investor Relations section.
  • Please go to the website 15 minutes early to register, download and install any necessary audio software.
  • If you are unable to listen live, a playback of the conference call can be accessed until May 25, 2021 at U.S.
  • Physical Therapy, Inc. operates 554 outpatient physical therapy clinics in 39 states.

Beacon Health Options Provides Needed Relief for Those Caught in Twin Pandemics of Opioid Use Disorder and COVID-19

Thursday, January 21, 2021 - 2:50pm

The crisis of increasing opioid use disorder (OUD) shows no sign of abating in Massachusetts.

Key Points: 
  • The crisis of increasing opioid use disorder (OUD) shows no sign of abating in Massachusetts.
  • Clearly, more needs to be done to save lives that are being taken prematurely by opioid use disorder.
  • In late 2019, to help address this ongoing crisis in Massachusetts, Beacon Health Options, a leading behavioral health services company headquartered in Boston, announced the distribution of $128,800 in grants to four community-based behavioral health organizations.
  • Beacon Health Options is a leading behavioral health services company serving 1 out of 9 people across all 50 states.

Hemolung® RAS Used to Treat More than 75 COVID-19 Patients

Thursday, January 21, 2021 - 2:05pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210121005186/en/
    The Hemolung RAS has enabled us to recover patients with COVID pneumonia during the pandemic.
  • The Hemolung RAS has given us a new tool during the current pandemic, to safely and easily treat our COVID-19 patients.
  • We were able to rapidly introduce the Hemolung RAS to our staff and start treating patients under Emergency Use Authorization.
  • For more information on the use of the Hemolung RAS for COVID-19 patients, please visit https://www.alung.com/covid-19/covid-19-us/
    *The Hemolung RAS has not been FDA cleared or approved.

RapidAI Enhancing Stroke Care Across Australia

Thursday, January 21, 2021 - 2:00pm

RapidAI, the leader in advanced imaging for stroke, today announced it now serves over 50 hospitals and teleradiology services in Australia.

Key Points: 
  • RapidAI, the leader in advanced imaging for stroke, today announced it now serves over 50 hospitals and teleradiology services in Australia.
  • Australia is a vast country and I am delighted to see more people having access to faster care irrespective of their postcode.
  • RapidAI makes the most-widely used advanced cerebrovascular imaging products for patient care, research, and clinical trials across the globe.
  • RapidAI clinical products help save lives, RapidAI workflow and messaging technologies help stroke teams save time, and RapidAI analytics and business intelligence products help stroke networks reduce costs and improve patient outcomes.

Turn Therapeutics Receives Authorization to Commence Human Trial for COVID-19 Therapeutic Candidate

Thursday, January 21, 2021 - 1:43pm

The prevention arms will assess Hexagens ability to prevent COVID-19 infection in frontline workers when worn intranasally as an adjunct to personal protective equipment.

Key Points: 
  • The prevention arms will assess Hexagens ability to prevent COVID-19 infection in frontline workers when worn intranasally as an adjunct to personal protective equipment.
  • While those who receive a vaccination may be protected if exposed, vaccines are not the end of this disease, said Bradley Burnam, CEO of Turn Therapeutics.
  • Turn Therapeutics is a concept-to-approval research and development organization focused on novel, best in class products for infection control, skin disease, and wound care.
  • Actual results, performance, or events may differ materially from those expressed or implied in such forward-looking statements.

Global Diagnostic Imaging Centers Industry (2020 to 2027) - Market Trajectory & Analytics - ResearchAndMarkets.com

Thursday, January 21, 2021 - 1:18pm

The "Diagnostic Imaging Centers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diagnostic Imaging Centers - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The 188-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.
  • This segment currently accounts for a 6% share of the global Diagnostic Imaging Centers market.
  • The U.S. Accounts for Over 28.8% of Global Market Size in 2020, While China is Forecast to Grow at a 8.2% CAGR for the Period of 2020-2027
    The Diagnostic Imaging Centers market in the U.S. is estimated at US$21.6 Billion in the year 2020.

EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea

Thursday, January 21, 2021 - 1:00pm

EuBiologics (KOSDAQ: 206650), a South Korean biotech company, announced on Jan 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial.

Key Points: 
  • EuBiologics (KOSDAQ: 206650), a South Korean biotech company, announced on Jan 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial.
  • View the full release here: https://www.businesswire.com/news/home/20210121005311/en/
    EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I/II clinical trial of a COVID-19 vaccine candidate EuCorVac-19 in Korea, immediately entering into the Phase I trial.
  • The EuCorVac-19 under development is a safe vaccine formulated with the coronavirus spike protein using recombinant protein technology and with a potent adjuvant.
  • EuBiologics also has a GMP accredited facility which can manufacture recombinant protein antigens and adjuvants, with confidence to provide competitive pricing.